Conflict of interest:
JP: Travel expenses and honoraria from Boehringer-Ingelheim, Genzyme, and Orion Pharma (all modest).
ML: Travel expenses from Bayer, Pfizer, MSD, Sanofi-Aventis; consultant to Boehringer-Ingelheim, Bayer, Pfizer, MSD, Sanofi-Aventis; and research contracts with Boehringer-Ingelheim and Sanofi-Aventis.
AM: Compensation for consultancy with Boehringer-Ingelheim.
KS: None declared.
JK: None declared.
R-JK: None declared.
MK: Honoraria and travel expenses for participating on the Steering Committee meetings of the PERFORM, CEPO, MCI-184-E04, and DIAS-4 trials, and for serving as a consultant for Boehringer-Ingelheim, Servier, Mitsubishi Pharma Europe Ltd, Siemens AG, Merck, and H. Lundbeck A/S (all modest).
TT: Scientific advisory boards for Boehringer-Ingelheim and Mitsubishi Pharma; consultant to Boehringer Ingelheim, PhotoThera, BrainsGate, Schering Plough, H. Lundbeck A/S, Sanofi-Aventis, and Concentric Medical (all modest); and research contracts with Boehringer Ingelheim, PhotoThera, BrainsGate, Schering Plough, H. Lundbeck A/S, Sanofi-Aventis, Concentric Medical, Mitsubishi Pharma (all significant).
DS: None declared.